JP2018526981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526981A5 JP2018526981A5 JP2018501159A JP2018501159A JP2018526981A5 JP 2018526981 A5 JP2018526981 A5 JP 2018526981A5 JP 2018501159 A JP2018501159 A JP 2018501159A JP 2018501159 A JP2018501159 A JP 2018501159A JP 2018526981 A5 JP2018526981 A5 JP 2018526981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cdr2
- cdr1
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021168124A JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500414 | 2015-07-15 | ||
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500414 | 2015-07-15 | ||
| DKPA201500416 | 2015-07-16 | ||
| DKPA201500416 | 2015-07-16 | ||
| EPPCT/EP2016/050296 | 2016-01-08 | ||
| PCT/EP2016/050296 WO2016110576A1 (en) | 2015-01-08 | 2016-01-08 | Bispecific antibodies against cd3 and cd20 |
| PCT/EP2016/066845 WO2017009442A1 (en) | 2015-07-15 | 2016-07-14 | Humanized or chimeric cd3 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168124A Division JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018526981A JP2018526981A (ja) | 2018-09-20 |
| JP2018526981A5 true JP2018526981A5 (enExample) | 2019-08-29 |
Family
ID=57757079
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501159A Pending JP2018526981A (ja) | 2015-07-15 | 2016-07-14 | ヒト化またはキメラｃｄ３抗体 |
| JP2021168124A Active JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A Pending JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168124A Active JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A Pending JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US11359015B2 (enExample) |
| EP (1) | EP3322727B1 (enExample) |
| JP (3) | JP2018526981A (enExample) |
| KR (2) | KR102786353B1 (enExample) |
| CN (3) | CN114989302B (enExample) |
| AU (2) | AU2016293073B2 (enExample) |
| BR (1) | BR112018000696A2 (enExample) |
| CA (1) | CA2992380A1 (enExample) |
| EA (1) | EA201890305A1 (enExample) |
| FI (1) | FI3322727T3 (enExample) |
| IL (2) | IL256562B2 (enExample) |
| MX (2) | MX395317B (enExample) |
| NZ (1) | NZ739028A (enExample) |
| UA (1) | UA128057C2 (enExample) |
| WO (1) | WO2017009442A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| HUE048722T2 (hu) | 2013-07-05 | 2020-08-28 | Genmab As | Humanizált vagy kiméra CD3 ellenanyagok |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| WO2018162749A1 (en) | 2017-03-09 | 2018-09-13 | Genmab A/S | Antibodies against pd-l1 |
| WO2018208877A1 (en) * | 2017-05-09 | 2018-11-15 | Yale University | Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| US10882907B2 (en) | 2017-06-21 | 2021-01-05 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
| WO2019025545A1 (en) | 2017-08-04 | 2019-02-07 | Genmab A/S | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE |
| CN111971298B (zh) | 2018-03-12 | 2025-06-20 | 健玛保 | 抗体 |
| CA3093330A1 (en) * | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
| US12377294B2 (en) * | 2018-08-28 | 2025-08-05 | Ambrx, Inc. | Anti-CD3 antibody folate bioconjugates and their uses |
| JP7774447B2 (ja) * | 2019-06-07 | 2025-11-21 | アディマブ・リミテッド・ライアビリティ・カンパニー | 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法 |
| EP4007772A4 (en) * | 2019-07-29 | 2023-11-29 | The Administrators Of The Tulane Educational Fund | ANTIBODIES TO CANDIDA AND USES THEREOF |
| WO2021048423A1 (en) | 2019-09-12 | 2021-03-18 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
| CA3168613A1 (en) * | 2020-03-18 | 2021-09-23 | Genmab A/S | Antibodies binding to b7h4 |
| CA3176436A1 (en) * | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
| JP2023541858A (ja) | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| US20240034812A1 (en) | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| MX2023003749A (es) * | 2020-10-02 | 2023-04-24 | Genmab As | Anticuerpos capaces de unirse al receptor huerfano 2 similar a tirosina-cinasa receptora (ror2) y anticuerpos biespecificos que se unen a ror2 y al cumulo de diferenciacion 3 (cd3). |
| EP4334359A1 (en) | 2021-05-07 | 2024-03-13 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3 |
| CN113527493B (zh) * | 2021-07-20 | 2023-10-27 | 广州爱思迈生物医药科技有限公司 | 一种b7-h3抗体及其应用 |
| US11814437B2 (en) * | 2021-10-08 | 2023-11-14 | Genmab A/S | Antibodies binding to CD30 and CD3 |
| CN115368446B (zh) * | 2022-07-19 | 2025-08-08 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| TW202506178A (zh) | 2023-04-05 | 2025-02-16 | 丹麥商珍美寶股份有限公司 | 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2139924B1 (en) | 2007-03-29 | 2016-07-06 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| CN102448984A (zh) | 2009-03-27 | 2012-05-09 | 酶遗传学股份有限公司 | 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法 |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| RU2608640C2 (ru) | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Способы получения мультиспецифичных и мультивалентных антител |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| CN107827985A (zh) | 2011-05-21 | 2018-03-23 | 宏观基因有限公司 | 能够与人和非人cd3结合的cd3结合分子 |
| HUE044633T2 (hu) | 2011-10-27 | 2019-11-28 | Genmab As | Heterodimer fehérjék elõállítása |
| DK2838917T3 (da) | 2012-04-20 | 2019-08-26 | Merus Nv | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler |
| WO2013186613A1 (en) * | 2012-06-14 | 2013-12-19 | Nasvax Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| WO2013188693A1 (en) * | 2012-06-15 | 2013-12-19 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| AU2013285355A1 (en) * | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| PT2869845T (pt) | 2012-07-06 | 2019-12-09 | Genmab Bv | Proteína dimérica com mutações triplas |
| ES2744267T3 (es) | 2012-11-21 | 2020-02-24 | Pharmabcine Inc | Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo |
| HUE048722T2 (hu) * | 2013-07-05 | 2020-08-28 | Genmab As | Humanizált vagy kiméra CD3 ellenanyagok |
| UA120286C2 (uk) | 2015-01-08 | 2019-11-11 | Ґенмаб А/С | Біспецифічне антитіло проти cd3 і cd20 |
-
2016
- 2016-07-14 AU AU2016293073A patent/AU2016293073B2/en active Active
- 2016-07-14 KR KR1020187004157A patent/KR102786353B1/ko active Active
- 2016-07-14 US US15/744,317 patent/US11359015B2/en active Active
- 2016-07-14 EP EP16739459.2A patent/EP3322727B1/en active Active
- 2016-07-14 UA UAA201801453A patent/UA128057C2/uk unknown
- 2016-07-14 MX MX2018000347A patent/MX395317B/es unknown
- 2016-07-14 WO PCT/EP2016/066845 patent/WO2017009442A1/en not_active Ceased
- 2016-07-14 CN CN202210585379.1A patent/CN114989302B/zh active Active
- 2016-07-14 FI FIEP16739459.2T patent/FI3322727T3/fi active
- 2016-07-14 KR KR1020257009196A patent/KR20250048113A/ko active Pending
- 2016-07-14 CN CN202511003204.5A patent/CN120842408A/zh active Pending
- 2016-07-14 NZ NZ739028A patent/NZ739028A/en unknown
- 2016-07-14 EA EA201890305A patent/EA201890305A1/ru unknown
- 2016-07-14 BR BR112018000696-3A patent/BR112018000696A2/en active Search and Examination
- 2016-07-14 CA CA2992380A patent/CA2992380A1/en active Pending
- 2016-07-14 IL IL256562A patent/IL256562B2/en unknown
- 2016-07-14 IL IL310467A patent/IL310467A/en unknown
- 2016-07-14 CN CN201680054638.0A patent/CN108368172B/zh active Active
- 2016-07-14 JP JP2018501159A patent/JP2018526981A/ja active Pending
-
2018
- 2018-01-09 MX MX2022011002A patent/MX2022011002A/es unknown
-
2021
- 2021-10-13 JP JP2021168124A patent/JP7604351B2/ja active Active
-
2022
- 2022-05-09 US US17/739,934 patent/US20230027394A1/en active Pending
- 2022-05-09 US US17/739,940 patent/US20220389101A1/en active Pending
- 2022-05-09 US US17/739,923 patent/US20220380464A1/en active Pending
-
2023
- 2023-03-20 AU AU2023201733A patent/AU2023201733A1/en active Pending
-
2024
- 2024-12-11 JP JP2024216521A patent/JP2025038049A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526981A5 (enExample) | ||
| JP2020048564A5 (enExample) | ||
| JP2016529882A5 (enExample) | ||
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| US9409979B2 (en) | Acceptor framework for CDR grafting | |
| JP2017505121A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| EP2050764A1 (en) | Novel polyvalent bispecific antibody format and uses thereof | |
| AU2020213579B2 (en) | Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| JP2020508655A5 (enExample) | ||
| JPWO2019129221A5 (enExample) | ||
| CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP2018522888A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| WO2021013142A1 (zh) | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 | |
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| US20220144956A1 (en) | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII | |
| US20240034815A1 (en) | Heterodimeric antibodies that bind cd3 and gpc3 | |
| JPWO2022111425A5 (enExample) | ||
| US20250084186A1 (en) | Anti-cd28 x anti-enpp3 antibodies | |
| CN113330037A (zh) | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 | |
| JP2016506974A (ja) | Ｃｄｒグラフトのためのアクセプターフレームワーク | |
| JPWO2022218380A5 (enExample) | ||
| WO2019072274A1 (zh) | 一种激动型4-1bb单克隆抗体 |